N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=127 Corticolimbic Degeneration and Treatment of Dementia
Dementia
Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095
Phase 2 N=41 A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
Alzheimer's Disease
Primary: Donepezil Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
N/A N=5,325 Digital Detection of Dementia (D Cubed) Studies: D2
Alzheimer Disease and Related Dementias (ADRD)
Primary: 12-Month Cumulative Incidence of ADRD Diagnoses — 213; 134; 355 Number of new ADRD cases — p=0.006
N/A N=104 Improvisational Movement for People With Memory Loss and Their Caregivers
Alzheimer's Disease (Incl Subtypes) · Dementia · Mild Cognitive Impairment
Primary: Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD) — 35.42; 38.10; 35.56; 36.12 score on a scale
N/A N=430 Dementia Symptom Management at Home Program
Dementia
Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale
Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
Phase 3 N=387 Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Agitation in Patients With Dementia of the Alzheimer's Type
Primary: Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12 — 73.9; 72.3; 71.7; -10.7 units on a…
Phase 3 N=522 Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Agitation in Participants With Dementia of the Alzheimer's Type
Primary: Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score — 73.7; 68.8; 71.3; -16.2 score on a scale — p=0.789
Phase 2 N=46 Dapagliflozin In Alzheimer's Disease
Alzheimer Disease
Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio
N/A N=30 Environmental Design for Behavioral Regulation in People With Dementia
Alzheimer Disease
Primary: Success Rate of Adherence — 2; 6; 7 Participants — p=0.12
N/A N=66 Care Coordination System for People With Dementia
Alzheimer Disease · Dementia · Dementia Alzheimers
Primary: Change in Baseline Burden and Stress of Caregivers Over 3 Months — -52.0; -31.9 percentage change
N/A N=42 Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
Mild Cognitive Impairment · Alzheimer Disease · Vascular Dementia
Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants
N/A N=20 SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
Mild Cognitive Impairment · Healthy Aging
Primary: Comprehension/Recall of Results - Personal Information Score - PARTICIPANT — 82.40; 94.60; 69.40; 90.80 percentage correct
Phase 3 N=402 DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
Alzheimer's Disease
Primary: Rate of Change on the ADAS-Cog 11. — 7.98; 8.27 ADAS points per year
Phase 2 N=75 Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Alzheimer's Disease
Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015
Phase 4 N=83 Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Mild Cognitive Impairment
Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
N/A N=884 Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
Dementia · Dementia, Vascular · Dementia With Lewy Bodies
Primary: Incidence of Hospital Transfers (Patients) — 0.99; 1.12 events per person day at risk — p=0.522
Phase 3 N=262 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…
N/A N=163 New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)
Alzheimer Disease · Behavioral Disorders · Cognitive Impairment
Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1
N/A N=352 A Non-pharmacological Intervention for Patients With Alzheimer's Disease and Family Caregivers (Care Partners Program)
Caregiver
Primary: Change in Depression Score for Caregiver as Measured by CES-D — 9; 10; 9; 8 units on a scale
Phase 2 N=28 A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
Dementia of Alzheimer's Type
Primary: Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort — 2; 0; 1; 6 Participants
Phase 4 N=81 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
Frontal Lobe Dementia · Frontotemporal Lobe Dementia · Semantic Dementia
Primary: Change in Neuropsychiatric Inventory (NPI) — -1.9; 0.3 units on a scale
Phase 2 N=263 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's Disease (AD)
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819
N/A N=10 Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer Disease
Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections
Phase 3 N=208 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
Dementia, Alzheimer Type
Primary: Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase — 12.12; 12.29; -5.52; -6.55 Units on a scale — p=0.802
N/A N=7 Palliative Care for Persons With ADRD and CI in SNF
Advance Care Planning · Palliative Care · Skilled Nursing Facility
Primary: Number of Participants That Completed Patient Quality of Life Survey — 4; 3; 3; 3 Participants
N/A N=4,497 Optimizing Care for Patients With Dementia
Alzheimer Disease
Primary: Dispensing of Psychotropic Medications — 161; 315 Participants — p=0.492